Immune booster after CAR-T shows promise in early lymphoma trial
NCT ID NCT05075603
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested an experimental drug called NT-I7 (efineptakin alfa) in 17 people with relapsed or refractory large B-cell lymphoma who had already received CAR-T cell therapy. The goal was to see if giving NT-I7 after CAR-T is safe and tolerable, and to look for early signs that it might help fight the cancer. The trial focused on finding the right dose and checking for side effects, not yet on proving the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Efineptakin alfa (NT-I7)
What this could lead to
If it works, this could point toward a way to boost the immune system after CAR-T therapy, potentially improving outcomes for people with hard-to-treat lymphoma.
What could go wrong
This is a very early, small phase 1 trial with only 17 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and there is a risk of side effects from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
City of Hope
Duarte, California, 91010, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States